The CAR-T Revolution

CAR-T therapies, a type of immunotherapy that uses genetically modified T cells to treat cancer, represent a paradigm shift in personalized medicine. It has the potential to teach your immune system to become a precision cancer-fighting machine. This therapy is currently FDA-approved to treat several types of hematological malignancies, including leukemia, lymphoma, and multiple myeloma and is being researched as a treatment for solid tumors, such as melanoma, lung cancer, and cervical cancer.

While groundbreaking, this treatment is incredibly complex to manufacture, and difficult to scale. It’s patient-specific, which leads to significant variability between patients, lengthy manufacturing times, and complex quality control measures. Given the complexity of the process, cloud-based digital manufacturing systems are well-suited to support CAR-T manufacturing by providing data insights, execution guidance, tracking and AI capabilities to optimize manufacturing processes.

Watch this week’s Industry Insights episode and learn more about this exciting advancement in medicine and the innovative ways the industry is delivering treatments to patients in need.